6 assets in Lymphoid Neoplasm

Therapeutic assets addressing Lymphoid Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Prednisone Lymphoid Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (52)
Venetoclax Lymphoid Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (52)
Enitociclib Lymphoid Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (49)
avm0703 Lymphoid Neoplasm	AVM Biotechnology Inc	P1/2	CCC (48)
rd13-02 cell infusion Lymphoid Neoplasm	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P1	CC (43)
aur104 Lymphoid Neoplasm	Aurigene Discovery Technologies Limited	P1	NR ()